D Klingbiel
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
19.02.2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
19.02.2019Lung Cancer 2019; 130:149-155
Schmid Sabine, Jochum Wolfram, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli Stefanie, Klingbiel D, Früh Martin
Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017
31.08.2017Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
31.08.2017Ann Oncol 2017
Klingbiel D, Thürlimann Beat, Brauchli P, von Moos R
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
19.12.2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
19.12.2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes K. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat 2016; 158:51-7.
08.06.2016Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
08.06.2016Breast Cancer Res Treat 2016; 158:51-7
Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015
08.12.2015The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
08.12.2015Ann Oncol 2015
Strasser Florian, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK)
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
29.05.2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
29.05.2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort
Cathomas R, von Moos R, Nagaraj N, Simmonds P, Wheater M, Ellis S, Mead G, Geldart T, Klingbiel D, Fehr M. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Ann Oncol 2014; 25:1591-7.
25.03.2014Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort
25.03.2014Ann Oncol 2014; 25:1591-7
Cathomas R, von Moos R, Nagaraj N, Simmonds P, Wheater M, Ellis S, Mead G M, Geldart T R, Klingbiel D, Fehr Martin